Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Thomson Medical Group Limited (A50.SI)
Singapore, SG
Operating as an investment holding company, Thomson Medical Group Limited delivers healthcare services specifically tailored for women and children across Singapore, Malaysia, and Vietnam. Its core assets include the Thomson Medical Centre, alongside an extensive network of affiliated medical clinics and healthcare facilities. The group's service portfolio encompasses immediate care solutions, covering basic resuscitation, ECG, vaccinations, intravenous fluid and antibiotic treatments, minor surgeries and procedures, wound management, and essential diagnostic imaging like X-rays and laboratory tests. Additionally, it provides comprehensive health screening, aesthetic and dermatological services, pain and rehabilitation management, and traditional herbal tea offerings. Furthermore, Thomson Medical Group specializes in a broad spectrum of medical areas. These include women's and children's health, fertility and family planning, ophthalmology, general surgery, urology, preventive health, healthy aging, advanced diagnostic imaging, breast care, cardiology, respiratory and critical care, endocrinology, dermatology, day surgery, general surgical care, counselling, therapy, Traditional Chinese Medicine (TCM), and specialized care for bone, joint, gynecological oncology, dental, and spine conditions. The company's diverse range of products and services are marketed under well-known brands such as Thomson Women's Clinic, Thomson Fertility Centre, Thomson Paediatric Clinic, Thomson Specialists, Thomson Chinese Medicine, Thomson Surgical Centre, Thomson Dental Centre, Thomson Hospital Kota Damansara, TMC Fertility, TMC Care Pharmacy, FV Hospital, and FV Saigon Clinic. Established in 1979, Thomson Medical Group Limited is headquartered in Singapore.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +1.82% | -1.75% | -5.08% | -1.75% | -6.67% | +30.23% | -6.67% | -37.08% | -57.89% | -57.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+12.4% ★ Q2'25: +19.9% (vs Q2'24)
-
EPS growth Medical - Care Facilities: +19.2%-460.0% Q2'25: -450.0% (vs Q2'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-11.7% Q2'25: +6.7% (vs Q2'24)
-
EBIT margin Medical - Care Facilities: +11.3%+4.8% Q2'25: -1.7% (vs Q2'24)
-
ROIC Medical - Care Facilities: +6.8%+1.2% Q2'25: -0.6% (vs Q2'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q2'25: -0.1% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×19.43× Q2'25: 130.75× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
351.15M
est: 350.00M (+0.3%)
|
394.66M
est: 405.70M (-2.7%)
|
428.30M
428.30M – 428.30M
+5.6% YoY
|
455.90M
455.90M – 455.90M
+6.4% YoY
|
456.20M
456.20M – 456.20M
+0.1% YoY
|
| EBITDA |
109.08M
est: 93.56M (+16.6%)
|
57.72M
est: 108.45M (-46.8%)
|
114.49M
114.49M – 114.49M
+5.6% YoY
|
121.87M
121.87M – 121.87M
+6.4% YoY
|
121.95M
121.95M – 121.95M
+0.1% YoY
|
| EBIT |
80.71M
est: 70.01M (+15.3%)
|
19.04M
est: 81.15M (-76.5%)
|
85.67M
85.67M – 85.67M
+5.6% YoY
|
91.19M
91.19M – 91.19M
+6.4% YoY
|
91.25M
91.25M – 91.25M
+0.1% YoY
|
| Net Income |
14.16M
|
-47.58M
est: -26.46M (-79.8%)
|
-23.81M
-23.81M – -23.81M
+10.0% YoY
|
-21.17M
-21.17M – -21.17M
+11.1% YoY
|
26.46M
26.46M – 26.46M
+225.0% YoY
|
| SGA |
-24.0K
est: -20.5K (-16.9%)
|
—
est: -23.8K (+100.0%)
|
-25.1K
-25.1K – -25.1K
-5.6% YoY
|
-26.7K
-26.7K – -26.7K
-6.4% YoY
|
-26.8K
-26.8K – -26.8K
-0.1% YoY
|
| EPS |
0.00
|
0.00
est: 0.00 (-80.0%)
|
0.00
0.00 – 0.00
+10.0% YoY
|
0.00
0.00 – 0.00
+11.1% YoY
|
0.00
0.00 – 0.00
+225.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 34.7K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 65.8K | 0.28% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 43.4K | 0.22% |
| 4 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chee Kien Seah | Managing Director of RSP Architecture & Design | — | male |
| Jun Li Heng | Group Chief Executive Officer & Executive Director | — | — |
| Kyra Huang | Director of Marketing & Communications | — | — |
| Swee Chiew Beh | Managing Director of RSP Civil & Structural Engineering | — | male |
| Sylvia Teo | Director of Corporate Human Resource | — | — |
| Teo Yann | Managing Director of Squire Mech Mechanical & Electrical Engineering | — | male |
| Wee Kiat Lim | Executive Vice-Chairman | — | male |
| Wilson Sam | Group Chief Financial Officer & Executive Director | — | male |
| Yu Chee Wong | Group Chief Financial Officer of TMC Life Sciences Berhad | — | male |
| Zing Yuen Tan | Chief Risk & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for A50.SI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
